BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35340167)

  • 1. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
    Zhang JW; Deng YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neoadjuvant immunotherapy for colorectal cancer].
    Pei JP; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer.
    Zhou L; Yang XQ; Zhao GY; Wang FJ; Liu X
    Front Immunol; 2023; 14():1044353. PubMed ID: 36776899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of neoadjuvant immunotherapy in advanced colorectal cancer: a meta-analysis of cross-sectional studies.
    Li Y; Xue C; Gao Z; Li K; Xu H; Zhu Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4839-4846. PubMed ID: 36260157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study.
    Lungulescu C; Croitoru VM; Volovat SR; Cazacu IM; Turcu-Stiolica A; Gheonea DI; Sur D; Lungulescu CV
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441055
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Díaz-Pérez D; Mateos-Dominguez M; Galindo-Jara P
    Eur J Surg Oncol; 2023 Feb; 49(2):323-328. PubMed ID: 36400657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and prospect of immunotherapy for colorectal cancer.
    Yang W; Zheng H; Lv W; Zhu Y
    Int J Colorectal Dis; 2023 Nov; 38(1):266. PubMed ID: 37962772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
    Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y
    Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
    Sillo TO; Beggs AD; Middleton G; Akingboye A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.